Non small cell lung cancer outcome
Epidermal growth factor receptor mutation, primary cancer pathology, and Recursive partitioning analysis class may be proposed as prognostic factors for intracranial progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients after GKRS for brain metastasis in a study 1).
Retrospective analysis of patients with Non small cell lung cancer (NSCLC) completely resected from lung found a 6.8 % first recurrence rate in the brain 2).
Prognosis better than small cell lung cancer (SCLC).
see also Non small cell lung cancer intracranial metastases outcome.
Between 25% and 30% of non-small cell lung cancer (NSCLC) patients will develop Non small cell lung cancer intracranial metastases.
Frequently they are the first site of recurrence in early-stage NSCLC patients treated with definitive therapies 3) 4) 5) 6) 7).
Non small cell lung cancer outcome is better than small cell lung cancer.
Given uniform staging, treatment, and socioeconomic status the overall survival rates for African American and White patients with NSLC are similar 8)
A significant excess mortality remains in lung cancer after years which may be explained by excess risk of death due to smoking-related comorbidity in these patients. Caregivers should use this information for planning optimal cancer surveillance and informing cancer survivors about their actual prognosis 9).
Retrospective analysis of patients with Non small cell lung cancer completely resected from lung found a 6,8 % first recurrence rate in the brain 10).